FDA Letter Puts Pressure on Medline After IPO Drop
Medline Inc. MDLN got hit with another warning letter from U.S. regulators Friday, the second warning in as many months. The back-to-back warnings put more heat on Medline’s quality control, just weeks after its IPO. The stock ended Thursday at $34.45, flat. Latest quote showed a 0.06% dip from the close. Medline’s timing is under a microscope. The firm listed on Nasdaq in December with 2025’s biggest IPO. Now, investors are watching to see if Medline’s hospital supply operation is large enough to weather regulatory noise, tariffs, and post-IPO selling. The stock is trading above the $29 IPO price but still distant from its $41 first-day close.